Time to Death: Continuous Tafamidis Versus Placebo to Tafamidis10
KM plot of observed time to all-cause mortality in ATTR-ACT and the LTE compared with a model-based extrapolation of time to all-cause mortality with placebo10
Survival Probability
Time to event (months)
Continuous tafamidis
Placebo to tafamidis
Extrapolated placebo
0.0
0.2
0.4
0.6
0.8
1.0
0
3
6
9
12
15
18
21
24
27
30
33
36
39
42
45
48
51
54
57
60
63
66
69
72
| Patients remaining at risk (cumulative events) |
|||||||||||||||||||||||||
| Continuous tafamidis |
176 | 172 | 170 | 164 | 155 | 148 | 144 | 139 | 132 | 128 | 117 | 107 | 104 | 99 | 95 | 91 | 85 | 78 | 72 | 56 | 30 | 17 | 6 | 1 | 0 |
| (0) | (4) | (6) | (12) | (21) | (28) | (32) | (37) | (44) | (48) | (54) | (56) | (59) | (63) | (66) | (69) | (73) | (74) | (75) | (78) | (78) | (78) | (78) | (79) | (79) | |
| Placebo to tafamidis |
177 | 173 | 171 | 163 | 161 | 150 | 141 | 131 | 118 | 113 | 93 | 77 | 70 | 62 | 58 | 54 | 51 | 45 | 36 | 29 | 15 | 8 | 0 | 0 | 0 |
| (0) | (4) | (6) | (14) | (16) | (27) | (36) | (46) | (59) | (64) | (75) | (81) | (88) | (95) | (99) | (102) | (104) | (106) | (110) | (110) | (110) | (111) | (111) | (111) | (111) | |
Median survival:
- Placebo to tafamidis: 35.8 months
- Continuous tafamidis: 67.0 months*
- Extrapolated placebo: 35.2 months
Results
- Survival curves for continuous tafamidis diverged from
placebo to tafamidis after ~17 months - Survival curves for placebo to tafamidis diverged from
extrapolated placebo after ~44 months (~14 months
after the start of the LTE) in favor of patients treated with placebo to tafamidis
*High degree of censoring prior to this point suggests estimate subject to change.
ATTR-ACT: Tafamidis in Transthyretin Cardiomyopathy Clinical Trial; ATTRwt-CM: wild-type transthyretin amyloid cardiomyopathy; KM: Kaplan Meier; LTE: long-term extension.
